Europe Human Primary Cells Market By Type (Blood (peripheral) cells, Endothelial cells, Epithelial cells, Fibroblast cells, Hepatocyte cells, Keratinocyte cells, Melanocyte cells, Pancreatic cells, Smooth muscle cells, Skeletal cells, Adipocyte cells), By Application (Medical, Clinical), Industry Trends, Estimation & Forecast, 2018 - 2025

August 2018

 Pages: 182

 ERC 6725


Europe Human Primary Cells Market is expected to grow with a CAGR of 6.1% during the forecast period of 2018 to 2025.

Europe is a region where strict regulations are implemented for the safety and well-being of any kind of living form. The sedentary lifestyle of people in the region has led to an increase in the prevalence of various curable and non-curable chronic diseases. Several diseases have found to affect the human organ systems such as heart, vascular system, blood, kidneys, skeleton, and musculature. The manipulation of human cells for cell and tissue replacement therapies holds great importance in the treatment of degenerative disease and injuries affecting the human organ systems. In the European Union (EU), gene- and cell-based therapies are defined as advanced therapy medicinal products. According to certain research, more than 4000 stem cell-based therapies are registered globally with the US NIH clinical trials database, of which a significant percentage (23%) of activity is within Europe. These clinical trials have a commercial sponsorship, with small- and medium-sized enterprises ascending in the European market. Moreover, various collaborative research projects, under the 6th Framework Programme (2002-2006) are funded by the European Union. These projects include stem cells that are studied or used as discovery means or biological tools. The clinical trials conducted in the EU are currently being governed by the Clinical Trials Directive, which will be overtaken by the Clinical Trial Regulation from 2019.

Regulations of human cell research in Europe vary from country to country. In the UK, the Medicines and Healthcare Products Regulatory Agency (MHRA) is responsible for authorizing clinical trials and inspecting and issuing the manufacturer's license for an Investigational Medicinal Product. In addition, the ethical approval is delivered by a Research Ethics Committee (REC), allowing an organization or researcher, in countries such as Wales, England, and Northern Ireland to procure, test, process, store, distribute and import/export tissues and cells, including cell lines. On the other hand, Spain has a comprehensive regulatory framework for stem cell research, with a series of laws and regulations applied to different aspects of research. There are two separate commissions with different functions in relation to stem cell research, such as guarantees commission for the donation and use of human cells, and tissues and national commission on assisted human reproduction. In Germany, the use of embryos for research is heavily restricted under the Embryo Protection Act, 1991, making the derivation of embryonic stem cell lines a criminal offence. Any applications to import stem cell lines for research must be approved by the Central Ethics Commission for Stem Cell Research (ZES), which comprises of scientists, physicians and experts in ethics. Whereas in France, while performing a research on human cells, two pieces of legislation must be taken into consideration. Firstly, the rules regarding research on human participants must be fulfilled (a written protocol must be submitted including the information document and the consent form). Secondly, specific rules apply to the collection of human material (including bio-banking activities).


Comparative Usage of Human Primary Cells in Major Applications

Major pharmaceutical companies are investing in gene- and cell-based therapy development in the European Union, however, recently a drop in the number of clinical trials held in the UK has been witnessed. This is expected to hamper the growth of human primary cells market in region.
The report provides detailed qualitative and quantitative analysis of the Europe human primary cells market. Market size and forecast in terms of value and volume has been provided for the period - (2017 - 2025), for the segments namely type, and application in each of the major regions.

Europe Human Primary Cells Market Player Analysis –

The report presents detailed analysis of major players operating in Europe human primary cells market. Few of them include Lonza, Thermo Fisher Scientific, Sigma-Aldrich, Cell Biologics, Promocell GmbH, Cureline, Zen-Bio, Stemcell Technologies, Cell Applications, Creative Bioarray, Reprocell Europe Ltd., and Tebu-Bio. A detailed coverage on these market players with information on their revenue from Europe human primary cells business, market share, gross margin and their growth strategies have been provided in the report.

Europe Human Primary Cells Market Segmentation

Europe human primary cells market is segmented on the basis of type, application, and geography. On the basis of type, the market is categorized into blood (peripheral) cells, endothelial cells, epithelial cells, fibroblast cells, hepatocyte cells, keratinocyte cells, melanocyte cells, pancreatic cells, smooth muscle cells, skeletal cells, and adipocyte cells. By application, the market is bifurcated into clinical and medical. Geographical coverage has been provided for each of the major regions including North America, Europe, Asia-Pacific, and Rest of the World.

Europe Human Primary Cells Market Segmentation

By Type
• Blood (peripheral) cells
• Endothelial cells
• Epithelial cells
• Fibroblast cells
• Hepatocyte cells
• Keratinocyte cells
• Melanocyte cells
• Pancreatic cells
• Smooth muscle cells
• Skeletal cells
• Adipocyte cells

By Application
• Medical
• Clinical

By Country
• U.K.
• France
• Germany
• Italy
• Spain
• Benelux
• Russia
• Rest of Europe

Europe Human Primary Cells Market Key Players

• Lonza
• Thermo Fisher Scientific
• Sigma-Aldrich
• Cell Biologics
• Promocell GmbH
• Cureline
• Zen-Bio
• Stemcell Technologies
• Cell Applications
• Creative Bioarray
• Reprocell Europe Ltd
• Tebu-Bio

Please fill in the form below to Request for Customized Report
Your personal details are safe and secured with us. Privacy Policy

To request sample copy of this report, please complete the form below verified and secure

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report. This also includes a 30 minute free analyst discussion post report purchase.

Your personal details are safe and secured with us. Privacy Policy

    What Information does this report contain?

    • What was the market size of the Europe Human Primary Cells Market in 2017 and the expected market size by 2025, along with the growth rate?
    • An in-depth analysis of the current impacting factors, opportunities and challenges/restraints in the market
    • Which are the largest revenue generating products, services or regions and their comparative growth rate?
    • Which technology is in trend and how would it evolve during the forecast period (2017 - 2025)?
    • Which are the leading companies in the Europe Human Primary Cells Market and their competitive positioning basis their market share, product portfolio, strategic attempts and business focus?

Purchase Options

Offers & Discounts

  • Chapter purchase
  • Historical market data
  • Country level data breakdown
  • Free customization*
  • Discounts for first time
  • Special pricing for
              non-business entities


  • We offer 20% free customization on every purchase.

Get in touch!